CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–Sep. 3, 2024– KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat…
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–Sep. 3, 2024– KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat…
No Comments
Leave a comment Cancel